[Federal Register Volume 87, Number 15 (Monday, January 24, 2022)]
[Notices]
[Pages 3549-3550]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01283]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


National Center for Health Statistics (NCHS), ICD-10 Coordination 
and Maintenance (C&M) Committee Meeting

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of virtual meeting.

-----------------------------------------------------------------------

SUMMARY: The CDC, National Center for Health Statistics (NCHS), 
Classifications and Public Health Data Standards Staff, announces the 
following meeting of the ICD-10 Coordination and Maintenance (C&M) 
Committee meeting. This meeting is open to the public, limited only by 
audio lines available. Online Registration is not required.

DATES: The meeting will be held on March 8, 2022, from 9:00 a.m. to 
5:00 p.m., EST, and March 9, 2022, from 9:00 a.m. to 5:00 p.m., EST.

ADDRESSES: This is a virtual meeting. Information will be provided on 
each of our respective web pages when it becomes available. For CDC/
NCHS https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm. For CMS 
https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings.

FOR FURTHER INFORMATION CONTACT: Traci Ramirez, Medical Systems 
Specialist, CDC, 3311 Toledo Road, Hyattsville, Maryland 20782, 
Telephone: (301) 458-4454; Email: <a href="/cdn-cgi/l/email-protection#8dd9dfece0e4ffe8f7cdeee9eea3eae2fb"><span class="__cf_email__" data-cfemail="c19593a0aca8b3a4bb81a2a5a2efa6aeb7">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION:
    Purpose: The ICD-10 Coordination and Maintenance (C&M) Committee is 
a public forum for the presentation of proposed modifications to the 
International Classification of Diseases, Tenth Revision, Clinical 
Modification and ICD-10 Procedure Coding System.
    Matters To Be Considered: The tentative agenda will include 
discussions on ICD-10-CM and ICD-10-PCS topics listed below. Agenda 
items are subject to change as priorities dictate. Please refer to the 
posted agenda for updates one month prior to the meeting.

ICD-10-PCS Topics

1. Administration of Spesolimab *
2. Administration of daratumumab and hyaluronidase-fihj *
3. Administration of Defencath *
4. Administration of Maribavir *
5. Administration of Teclistamab *
6. Administration of Mosunetuzumab *
7. Administration of afamitresgene autoleucel **
8. Administration of tabelecleucel **
9. Administration of Treosulfan *
10. Administration of inebilizumab-cdon *
11. Administration of Xenon-129 *
12. Administration of betibeglogene autotemcel **
13. Administration of Omidubicel **
14. Implantation of Sphenopalatine Ganglion Stimulator for Ischemic 
Stroke *
15. Gene Expression Assay **
16. Vertebral Body Tethering *
17. Percutaneous Femoral-Popliteal Artery Bypass *
18. Computer-Assisted Transcranial Magnetic Stimulation *
19. Computer-Aided Analysis for the Detection and Classification of 
Epileptic Events *
20. Facet Replacement Spinal Stabilization Device *
21. Insertion of Sacropelvic Fixation System *
22. Insertion of an Implantable Vagus Nerve Stimulation System *
23. Insertion of a Paired Vagus Nerve Stimulation System *
24. Percutaneous Venous Thrombectomy for Postthrombotic Syndrome *
25. Quantitative Flow Ratio for Non-invasive Intraprocedural 
Analysis of Cardiac Angiography
26. Application of Allogeneic Thymus Derived Tissue
27. Supersaturated Oxygen Therapy
28. Assistance with Precision Stimulation Software *
29. Section X Updates
30. Addenda and Key Updates

    * Requestor has submitted a New Technology Add-on Payment (NTAP) 
application for FY 2023.
    ** Requestor intends to submit an NTAP application for FY 2024 
consideration.
    Presentations for procedure code requests are conducted by both the 
requestor and CMS during the Coordination & Maintenance Committee 
meeting. Discussion from the requestor generally focuses on the 
clinical issues for the procedure or technology, followed by the 
proposed coding options from a CMS analyst. Topics presented may also 
include requests for new procedure codes that relate to a new 
technology add-on payment (NTAP) policy request.
    CMS is continuing to modify the approach for presenting the new 
technology add-on payment (NTAP) related ICD-10-PCS procedure code 
requests that involve the administration of a therapeutic agent for the 
March 8-9, 2022 ICD-10 Coordination and Maintenance Committee meeting. 
Consistent with the requirements of section 1886(d)(5)(K)(iii) of the 
Social Security Act, applicants submitted requests to create a unique 
procedure code to describe the administration of a therapeutic agent, 
such as the option to create a new code in Section X within the ICD-10-
PCS procedure code classification. CMS will initially only display 
those meeting materials associated with the NTAP related ICD-10-PCS 
procedure code requests that involve the administration of a 
therapeutic agent on the CMS website in early February 2022 at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials.
    The 13 NTAP related ICD-10-PCS procedure code requests that involve 
the administration of a therapeutic agent are:

1. Administration of Spesolimab *
2. Administration of daratumumab and hyaluronidase-fihj *
3. Administration of Defencath *
4. Administration of Maribavir *
5. Administration of Teclistamab *
6. Administration of Mosunetuzumab *
7. Administration of afamitresgene autoleucel **
8. Administration of tabelecleucel **
9. Administration of Treosulfan *
10. Administration of inebilizumab-cdon *
11. Administration of Xenon-129 *
12. Administration of betibeglogene autotemcel **
13. Administration of Omidubicel **

    These topics will not be presented during the March 8-9, 2022 
meeting. CMS will solicit public comments regarding any clinical 
questions or coding options included for these 13 procedure code topics 
in advance of the meeting continuing through the end of the public 
comment period, April 8, 2022. Members of the public should send any 
questions or comments to the CMS mailbox at: ICDProcedure 
<a href="/cdn-cgi/l/email-protection#93d0fcf7f6c1f6e2e6f6e0e7d3f0fee0bdfbfbe0bdf4fce5"><span class="__cf_email__" data-cfemail="4a09252e2f182f3b3f2f393e0a29273964222239642d253c">[email protected]</span></a> by the April 8, 2022 deadline.
    CMS intends to post a question and answer document in advance of 
the meeting to address any clinical or coding questions that members of 
the public may have submitted. Following the conclusion of the meeting, 
CMS will post an updated question and answer document to address any 
additional clinical or coding questions that members of the public may 
have submitted during the meeting that CMS was not able to address or 
that were submitted after the meeting.
    The NTAP related ICD-10-PCS procedure code requests that do not 
involve the administration of a

[[Page 3550]]

therapeutic agent and all non-NTAP related procedure code requests will 
continue to be presented during the virtual meeting on March 8, 2022, 
consistent with the standard meeting process.
    CMS will make all meeting materials and related documents available 
at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials. Any inquiries related to the procedure code topics scheduled 
for the March 8-9, 2022 ICD-10 Coordination and Maintenance Committee 
meeting that are under consideration for October 1, 2022 implementation 
should be sent to the CMS mailbox at: ICDProcedure 
<a href="/cdn-cgi/l/email-protection#81c2eee5e4d3e4f0f4e4f2f5c1e2ecf2afe9e9f2afe6eef7"><span class="__cf_email__" data-cfemail="9ddef2f9f8cff8ece8f8eee9ddfef0eeb3f5f5eeb3faf2eb">[email protected]</span></a>.

ICD-10-CM Topics

1. Coma
2. Craniosynostosis
3. Extraocular muscle entrapment
4. Foreign body sensation
5. Impairing Emotional Outbursts
6. Insulin resistant syndrome
7. Leukodystrophies
8. Observation and evaluation of newborn for other specified 
suspected condition ruled out
9. Problems related to upbringing
10. Addenda

    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-01283 Filed 1-21-22; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>